STAN1 + gluten

STAN1 + gluten appears to refer to a combination of the investigational drug STA-1 (also referred to as STAN1) and gluten. STA-1 is a chemical drug initially developed by Sinphar Pharmaceutical for potential use in nervous system diseases and cardiovascular diseases. Preclinical studies suggest that STA-1 may suppress allergen-induced immunoglobulin E (IgE) synthesis, airway inflammation, and hyperreactivity in animal models of allergic asthma. It has also been investigated as an add-on treatment to donepezil in patients with mild to moderate Alzheimer's disease, reaching Phase 2 clinical trials. The mechanism of action for STA-1 is not fully elucidated but involves modulation of immune responses related to allergy and possibly neuroprotection or anti-inflammatory effects relevant for Alzheimer's disease. There is no evidence that "STAN1 + gluten" is an approved or widely recognized pharmaceutical product; the addition of "gluten" may be experimental or hypothetical.